Pacific Biosciences
PACB
236 hedge funds and large institutions have $1.83B invested in Pacific Biosciences in 2022 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 65 increasing their positions, 77 reducing their positions, and 29 closing their positions.
69% more call options, than puts
Call options by funds: $24.6M | Put options by funds: $14.5M
49% more capital invested
Capital invested by funds: $1.23B → $1.83B (+$598M)
48% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 29
5.23% more ownership
Funds ownership: 94.23% → 99.45% (+5.2%)
4% more funds holding
Funds holding: 227 → 236 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
16% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 77
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$36.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$34.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$24.1M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$13.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$9.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSP
Jackson Square Partners
Larkspur,
California
|
-$45.3M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$25.9M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$20.2M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$12.9M |
| 5 |
DM
Deerfield Management
New York
|
-$11.7M |
PACB Hedge Fund Activity: Q4 2022 in Review
236 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2022, worth a combined $1.83B — up 49% from $1.23B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new PACB positions and 29 closed out — a net gain of 14 holders — while 65 added to existing stakes and 77 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $36.3M. The largest seller was Jackson Square Partners, cutting an estimated $45.3M.
- 236 institutional investors held Pacific Biosciences (PACB) as of Q4 2022, up from 227 in Q3 2022.
- Funds reported $1.83B of Pacific Biosciences stock for Q4 2022, up 49% quarter-over-quarter.
- 43 funds opened new Pacific Biosciences positions in Q4 2022 and 29 closed out, a net change of +14 holders.
- The largest Pacific Biosciences buyer in Q4 2022 was Lord, Abbett & Co, an estimated $36.3M added.
- The largest Pacific Biosciences seller in Q4 2022 was Jackson Square Partners, an estimated $45.3M sold.
Based on aggregated 13F filings for Q4 2022.